Front Oncol: The effect of primary tumor location (PTL) on the posterior line of mCRC patients with REG or FTD/TPI treatment

Primary tumor location (PTL) is an important prognostic and predictive factor in the first-line treatment of metastatic colorectal cancer (mCRC) .
In post-line treatment, regorafenib (REG) and trifluridine/tipiracil (Trifluridine hydrochloride/tipiracil compound tablets, FTD/TPI) improved the prognosis of patients compared with placebo .
However, the clinical impact of PTL in these two treatment modalities is unclear .
Recently, a related study was published in Frontiers in Oncology magazine, aiming to evaluate the prognostic and predictive value of PTL in patients with mCRC in the REGOTS study for subsequent treatment with REG or FTD/TPI .

Primary tumor location (PTL) is an important prognostic and predictive factor in the first-line treatment of metastatic colorectal cancer (mCRC) .

In post-line treatment, both regorafenib (REG) and trifluridine/tipiracil (Trifluridine Hydrochloride/Tipyridine Compound Tablets, FTD/TPI) improved the prognosis of patients compared with placebo .
However, the clinical impact of PTL in these two treatment modalities is unclear .
Recently, a related study was published in Frontiers in Oncology magazine, aiming to evaluate the prognostic and predictive value of PTL in patients with mCRC in the REGOTS study for subsequent treatment with REG or FTD/TPI .
Primary tumor location (PTL) is an important prognostic and predictive factor in the first-line treatment of metastatic colorectal cancer (mCRC) .
In post-line treatment, regorafenib (regorafenib, REG) and trifluridine/tipiracil (trifluridine hydrochloride/tipiracil compound tablets, FTD/TPI)

The study retrospectively evaluated patients with mCRC enrolled in a multicenter observational study (REGOTAS study ) .

Inclusion criteria: ECOG 0-2 points, 5-FU , oxaliplatin, irinotecan, anti- vascular therapy, anti- EGFR therapy ( RAS wild) and other drugs are resistant or intolerable, have not used REG and FTD/ TPI .
Based baseline characteristics Cox proportional hazards model to assess PTL overall survival (OS) effects .

The study retrospectively evaluated patients with mCRC enrolled in a multicenter observational study (REGOTAS study ) .
Inclusion criteria: ECOG 0-2 points, 5-FU , oxaliplatin, irinotecan, anti- vascular therapy, anti- EGFR therapy ( RAS wild) and other drugs are resistant or intolerable, have not used REG and FTD/ TPI .
Based baseline characteristics Cox proportional hazards model to assess PTL overall survival (OS) effects .
The study retrospectively evaluated patients with mCRC enrolled in a multicenter observational study (REGOTAS study ) .
Inclusion criteria: ECOG 0-2 points, 5-FU , oxaliplatin, irinotecan, anti- vascular therapy, anti- vascular EGFR therapy ( RAS

A total of 550 patients (223 in the REG group and 327 in the FTD/TPI group)

In the overall cohort (REG and FTD/TPI groups), the median OS of the right tumor was 5.

Prognostic factors

Prognostic factors Prognostic factors

In the right tumor, the median OS in the REG group was 5.
7 months (4.
5-7.
8), and the median OS in the FTD/TPI group was 6.
0 months (5.
3-7.
7) (unadjusted HR was 0.
93 [95% CI 0.
62-1.
39] ], log-rank p = 0.
71)
.

In the left tumor, the median OS in the REG group was 8.

In the right tumor, the median OS in the REG group was 5.

         OS of tumors on the right and left

         OS for right and left tumors OS for right and left tumors

In the right tumor, the progression-free survival (PFS) of the FTD/TPI group tended to be longer (unadjusted HR=0.
71 [95% CI 0.
48-1.
05], log-rank p=0.
086)
.

In the left tumor, there was no statistical difference in PFS between the two treatment groups (unadjusted HR=1.

In the right tumor, the progression-free survival (PFS) of the FTD/TPI group tended to be longer (unadjusted HR=0.

Target lesion ( right tumor 112 cases tumors on the left side 407 embodiment ) no complete remission, the tumor left row FTD / TPI treatment .

A total of 174 patients in

In summary, studies have shown that primary tumor location (PTL) is not a prognostic and predictive factor for mCRC patients with subsequent treatment with REG or FTD/TPI

Original source:

Nakajima H, Fukuoka S, Masuishi T, et al (2021) Clinical Impact of Primary Tumor Location in Metastatic Colorectal Cancer Patients Under Later-Line Regorafenib or Trifluridine/Tipiracil Treatment.

Nakajima H, Fukuoka S, Masuishi T, et al (2021) Clinical Impact of Primary Tumor Location in Metastatic Colorectal Cancer Patients Under Later-Line Regorafenib or Trifluridine/Tipiracil Treatment.
Front.
Oncol.
11:688709.
doi: 10.
3389/fonc.
2021.
688709 leave a message here